Copertina

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Mustafa Mohamedrashed, Leya Nedumannil, Mayur Garg
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply
di: Annalisa Schiepatti, et al.
Pubblicazione: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find
di: Leya Nedumannil, et al.
Pubblicazione: (2024)

Systematic review: Clinical phenotypes, histopathological features and prognosis of enteropathy due to angiotensin II receptor blockers
di: Annalisa Schiepatti, et al.
Pubblicazione: (2024)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
di: Ziheng Calvin Xu, et al.
Pubblicazione: (2025)

Review article: Faecal biomarkers for assessing small intestinal damage in coeliac disease and environmental enteropathy
di: Laura Kivelä, et al.
Pubblicazione: (2024)

Non‐selective beta‐blocker is associated with reduced mortality in critically ill patients with cirrhosis: A real‐world study
di: Rahul Kumar, et al.
Pubblicazione: (2024)

No value of non‐selective beta‐blockers after TIPS‐insertion
di: Anja Tiede, et al.
Pubblicazione: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
di: Yaomin Wang, et al.
Pubblicazione: (2024)

Letter: Addressing opioid exposure and associated harms in patients with IBD
di: Christian P. Selinger, et al.
Pubblicazione: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
di: Abdel‐Aziz Shaheen, et al.
Pubblicazione: (2024)

Editorial: Non‐selective beta‐blockers: A lifesaving shield for critically ill patients with acute decompensation of cirrhosis?
di: Ling Yang, et al.
Pubblicazione: (2024)

Impact of non‐selective beta blockers on further decompensation and death in decompensated cirrhosis: Benefit and risk stratification by MELD score
di: Ting Wang, et al.
Pubblicazione: (2024)

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon
di: D. Bogatic, et al.
Pubblicazione: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
di: Rui Zhang, et al.
Pubblicazione: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
di: Parminder Kaur, et al.
Pubblicazione: (2024)

Letter: Irritable bowel syndrome and antibiotics
di: George F. Longstreth
Pubblicazione: (2024)

Letter: Intestinal Ultrasound‐Prioritising Progress
di: Kacie H. Denton, et al.
Pubblicazione: (2026)

Letter: Resmetirom for treatment of MASH with children and adolescents
di: Yong‐Hai Zhou, et al.
Pubblicazione: (2024)

Letter: Steroid Tapering—Is Shorter Duration Better?
di: Juntao Lu, et al.
Pubblicazione: (2026)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
di: Kyle Staller, et al.
Pubblicazione: (2024)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
di: Tamar Schildkraut, et al.
Pubblicazione: (2024)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
di: Richard Pollok
Pubblicazione: (2025)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition?
di: Fernanda Cristofori, et al.
Pubblicazione: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors?
di: Mathieu Uzzan, et al.
Pubblicazione: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
di: Christophe Corpechot
Pubblicazione: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
di: Ewan Forrest, et al.
Pubblicazione: (2025)

Letter: Muddle of serum sPD‐1 and sPD‐L1 levels and association with HBsAg clearance in HBeAg‐negative CHB patients on IFN therapy
di: Ankur Jindal
Pubblicazione: (2024)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
di: Jiamei Wang, et al.
Pubblicazione: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
di: Mingsi Zhang, et al.
Pubblicazione: (2024)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
di: Muhammad Osama, et al.
Pubblicazione: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively?
di: David Laharie
Pubblicazione: (2024)

Letter: Why Assessment of ChILI Severity Accurately Matters?
di: Mar Riveiro‐Barciela, et al.
Pubblicazione: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
di: Zhuo Li, et al.
Pubblicazione: (2024)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
di: Jiru Li, et al.
Pubblicazione: (2025)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
di: Kuan‐Ju Lin, et al.
Pubblicazione: (2025)

Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease
di: Finlay Macrae
Pubblicazione: (2025)

Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies
di: Guofu Mao, et al.
Pubblicazione: (2026)

Letter: Identifying the Best Model for Predicting Post‐SVR HCC
di: Hidenori Toyoda
Pubblicazione: (2025)

Letter: TB‐CD Puzzle—Is tNGS the Final Piece?
di: Abhishek Yadav, et al.
Pubblicazione: (2025)

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
di: Deliang Huang, et al.
Pubblicazione: (2026)